ISTH announced new editors for its flagship publication, the Journal of Thrombosis and Haemostasis (JTH)

ISTH announced new editors for its flagship publication, the Journal of Thrombosis and Haemostasis (JTH)

The International Society on Thrombosis and Haemostasis (ISTH) announced Suzanne Cannegieter, M.D., Ph.D., M.Sc. and Ton Lisman, Ph.D., as the new editors-in-chief for its flagship scientific medical publication, the Journal of Thrombosis and Haemostasis (JTH) celebrating its 20th anniversary. The internationally regarded journal is a resource publishing cutting edge basic, translational and clinical research in the fields of bleeding and clotting disorders. The incoming editors will work alongside the current editors-in-chief and begin their term on January 1, 2024.

“During the thorough application and selection process, expertly led by the Chair, Wolfram Ruf, M.D., Ph.D, and Co-Chair, Cécile Denis, Ph.D., along with the ISTH Publications Committee, we received several excellent applications from highly qualified candidates from around the world,” said Flora Peyvandi, M.D., Ph.D., ISTH President. “We are proud of the significant contributions of the JTH’s current editors-in-chief, David Lillicrap, M.D. and Jim Morrissey, Ph.D., and we appreciate their tremendous achievements. As we look ahead, we are thrilled to announce Suzanne Cannegieter, the first woman JTH editor, and Ton Lisman who will be outstanding ambassadors of the journal, providing innovative vision and leadership.”

The JTH is an integral component of the ISTH’s mission to advance the understanding of thrombosis, hemostasis and related conditions by publishing high-quality, original research reports, state-of-the-art reviews, letters, announcements, invited commentaries and debates on timely topics in a hybrid subscription-based model. JTH achieved a historic high Impact Factor of 16.036 in 2022, a citation measurement indicating a publication’s scientific impact, and currently ranks fifth overall in the Hematology subject category and third in the Peripheral Vascular Disease category.

“Ton and I are confident that our combined broad interest in the field and our extensive international network will help to strengthen JTH further by building on the remarkable achievements of previous editorial teams,” said Suzanne Cannegieter, M.D., Ph.D. “Our predecessors have created a successful path in which to follow, and the journal has done exceptionally well during the past four years as a result of their leadership. We intend to maintain many of the changes that they have implemented and capitalize on the remarkable rise of JTH’s Impact Factor. I am also incredibly proud to hold the title of the first woman editor-in-chief in JTH’s history and look forward to continuing to promote diversity, equity and inclusion in the field.”

Suzanne Cannegieter is a Professor of Clinical Epidemiology at Leiden University Medical Center in The Netherlands. Her achievements are internationally recognized by high-ranked journals, invitations to speak at large international meetings, and long-lasting collaborations with world renowned investigators. Cannegieter has served as an associate editor of ISTH’s newest journal, Research and Practice in Thrombosis and Haemostasis, since its launch in 2018, and is also on the journal editorial boards of JTH, HemaSphere and the academic editor for PLOS Medicine.

“We have several combined goals for the journal one of which is to strengthen the connection between the journal and the ISTH and increase the visibility of JTH as a society journal, for example by publishing a series of manuscripts dedicated to the educational activities of the society,” shared Ton Lisman, Ph.D. “We will also prioritize mentoring programs for Early Career and Reach-the-World investigators, a program for professionals in resource challenged countries, to increase diversity amongst our reviewers and editors. In addition, we will actively encourage submission of studies on a variety of topics from other specialties to increasingly capture the interdisciplinary importance of thrombosis and hemostasis.” 

Ton Lisman was trained as a biochemist and currently serves as Professor of Experimental Surgery with special reference to the pathophysiology of thrombosis and hemostasis at the University Medical Center Groningen in the Netherlands. Lisman has served on clinical guideline committees of three large international societies, has founded and is the Chair of the ISTH Scientific and Standardization Subcommittee on Hemostatic Management of Patients with Liver Diseases and served as an associate editor for JTH since 2014.

To learn more about the JTH and ISTH, visit

Previous Article ISTH announced new editor for its open access online publication, Research and Practice in Thrombosis and Haemostasis (RPTH)
Next Article Oxygen versus ambient air in patients with intermediate-risk acute pulmonary embolism: The AIR randomized clinical trial